Results
88
Companys with strong funding and high growth potential
88 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 234.60 | 3.4% | -19.9% | SEK 20.8b | SEK 368.63 | PS82x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.10 | -9.1% | -6.8% | US$143.2m | US$9.23 | PB0.7x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$5.28 | -12.3% | 60.0% | US$1.8b | US$12.50 | PS7.8x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 22.00 | 4.8% | -15.3% | SEK 20.8b | SEK 34.39 | PS82.4x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
LEGN | US$44.74 | 2.8% | -35.0% | US$8.4b | US$82.50 | PS23.8x | E63.7% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.5b | n/a | PS2.9x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.68 | 0.9% | n/a | HK$60.9b | HK$29.24 | PS9.1x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$271.67 | -3.0% | 20.3% | US$6.0b | US$365.07 | PB6.8x | E63.8% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.25 | -2.4% | -59.3% | US$193.1m | US$9.25 | PB1.7x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.66 | 13.2% | 28.7% | US$845.9m | US$19.00 | PS83911.3x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$7.88 | -0.8% | -52.4% | US$200.3m | US$23.22 | PS4x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$3.94 | -6.4% | -41.5% | US$263.7m | US$21.20 | PS22.3x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$8.09 | 1.6% | -48.0% | US$630.3m | US$14.86 | PS4x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$15.84 | 1.5% | -34.0% | US$2.7b | US$27.35 | PS3.2x | E41.5% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.38 | -11.9% | 16.7% | US$91.4m | US$15.25 | PB9.4x | E66.9% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$39.73 | 2.0% | 846.0% | US$1.5b | US$67.29 | PB10.1x | E65.2% | n/a | Pharmaceuticals & Biotech | ||
PGEN | US$1.49 | -10.8% | 31.9% | US$391.3m | US$10.12 | PS69.1x | E58.5% | n/a | Pharmaceuticals & Biotech | ||
0IV3 | US$4.22 | -9.0% | 31.3% | US$2.6b | US$7.01 | PS4756.5x | E65.1% | n/a | Pharmaceuticals & Biotech |